Product image of Naegoti (Fingolimod) supplied by GNH India

Naegoti

Active Ingredient:
Fingolimod
Origin:
EU

Naegoti (Fingolimod)

Fingolimod, the active ingredient in Naegoti, is a sphingosine‑1‑phosphate receptor modulator presented as an oral formulation for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients.
GNH India supplies Naegoti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medac Pharma Srl

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Naegoti (fingolimod) acts on the sphingosine‑1‑phosphate pathway to modify disease activity in multiple sclerosis.

  • Relapsing‑Remitting Multiple Sclerosis: reduces the frequency of clinical relapses and slows MRI lesion accumulation.
  • Secondary Progressive Multiple Sclerosis with active disease: delays disability progression and lowers relapse risk.
  • Clinically Isolated Syndrome at high risk of conversion: postpones the onset of definitive multiple sclerosis.

How It Works

  • Fingolimod is phosphorylated in vivo to fingolimod‑phosphate, which binds with high affinity to sphingosine‑1‑phosphate (S1P) receptors 1, 3, 4 and 5. Functional antagonism of S1P1 on lymphocytes traps them within lymph nodes, reducing their migration into the central nervous system and thereby diminishing neuroinflammatory activity associated with multiple sclerosis.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity, often transient.
  • Nausea: occasional, may improve with food.
  • Diarrhea: usually self‑limiting.
  • Fatigue: persistent tiredness reported by some patients.
  • Upper respiratory tract infection: mild cold‑like symptoms.
  • Elevated liver enzymes: mild transaminase rise detected in routine labs.

Serious or Rare Side Effects

  • Severe infections: opportunistic or serious bacterial infections.
  • Cardiac arrhythmia: bradycardia or heart block, especially after first dose.
  • Macular edema: visual disturbances requiring ophthalmologic evaluation.
  • Significant liver injury: marked transaminase elevation or hepatitis.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.
  • Respiratory complications: severe asthma or bronchospasm.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline status and monitor for specific risks.

  • Liver monitoring: perform baseline and periodic liver function tests during treatment.
  • Cardiac evaluation: obtain ECG and monitor heart rate after the first dose, especially in patients with cardiac history.
  • Infection screening: evaluate for active infections and vaccinate appropriately before starting.
  • Pregnancy counseling: discuss potential fetal risks and advise effective contraception.
  • Live vaccine avoidance: do not administer live attenuated vaccines while on therapy.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Fingolimod may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase fingolimod exposure.
  • Live vaccines: risk of uncontrolled infection due to immunosuppression.
  • Drugs that prolong QT interval (e.g., certain antiarrhythmics): may exacerbate cardiac effects.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
  • Antihypertensive agents: potential additive blood pressure effects.
  • Antiplatelet or anticoagulant drugs: increased bleeding risk.
  • Non‑live vaccines: monitor immune response, may be attenuated.

Frequently Asked Questions

Naegoti contains fingolimod, which is prescribed to treat relapsing forms of multiple sclerosis, including relapsing‑remitting disease, secondary progressive disease with active lesions, and clinically isolated syndrome at high risk of conversion to multiple sclerosis.

Fingolimod is converted to its active phosphate form, which binds to sphingosine‑1‑phosphate receptors on lymphocytes. This prevents the cells from leaving lymph nodes, thereby reducing their entry into the central nervous system and lowering neuroinflammation that drives multiple sclerosis activity.

The specific dose and dosing schedule for Naegoti are determined by the prescribing clinician based on the patient’s condition, weight, and response to therapy. The prescriber will provide individualized dosing instructions.

Safety data for fingolimod in pregnancy and lactation are limited. Women of childbearing potential should use effective contraception while on therapy, and the drug should only be used during pregnancy if the potential benefit justifies the potential risk. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Naegoti (fingolimod) is an oral sphingosine‑1‑phosphate receptor modulator, offering a convenient once‑daily tablet compared with injectable disease‑modifying agents. Its efficacy in reducing relapse rates is comparable to some high‑efficacy injectables, but safety profiles differ, particularly regarding cardiac and infection risks, which must be weighed by the treating physician.

Naegoti should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not refrigerate or freeze the product. Keep it out of reach of children and dispose of any unused tablets according to local regulations.

Naegoti is taken orally, usually as a single tablet taken once daily with or without food, as directed by the prescribing physician. Patients should follow the prescriber’s instructions regarding timing and any necessary monitoring after the first dose.

The most serious risks include severe infections, cardiac arrhythmias (especially bradycardia after the first dose), macular edema affecting vision, significant liver injury, and the rare but potentially fatal progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for these complications.

Naegoti is contraindicated in patients with known hypersensitivity to fingolimod or any of its excipients, those with recent myocardial infarction, unstable angina, stroke, or uncontrolled cardiac disease, as well as individuals with active infections, severe liver impairment, or who are pregnant without a clear benefit outweighing risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT